САВУСТЬЯНЕНКО А.В., к.м.н., Донецкий национальный медицинский университет им. М. Горького
Журнал «Артериальная гипертензия»
1(3) 2009 / Лекция
1. Sonoda M., Aoyagi T., Takenaka K. et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors) // Int. Heart. J. — 2008. — Vol. 49, № 1. — P. 95-103.
2. Brooke B.S., Habashi P., Judge D.P. et al. Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2787-2795.
3. Berl T. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers // Nephrol. Dial. Transplant. — 2008 — Vol. 23. — P. 2443‑2447.
4. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol / Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. // Lancet. — 2002. — Vol. 359. — P. 995-1003.
5. Dobovisek J., Kanic V., Niegowska J. et al. Efficacy and Tolerability of Losartan in Patients with Essential Hypertension: a Multicentre, Double-Blind Comparison of Losartan with Metoprolol // Journal of Clinical and Basic Cardiology. — 2005. — Vol. 8 (Issue 1–4). — P. 43-46.
6. Grote K., Drexler H., Schieffer B. Renin-angiotensin system and atherosclerosis // Nephrol. Dial. Transplant. — 2004. — Vol. 19. — P. 770-773.
7. Jin H.-M., Pan Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy // Nephrol. Dial. Transplant. — 2007. — Vol. 22. — P. 1943-1949.
8. Devereux R.B., Dahlof B., Gerdts E. et al. Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol (The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial // Circulation. — 2004. — Vol. 110. — P. 1456-1462.
9. Hou F.F., Xie D., Zhang X. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency // Am. Soc. Nephrol. — 2007. — Vol. 18. — P. 1889-1898.